Conjunctivitis Drugs Market Research Report - Forecast till 2027

Conjunctivitis Drugs Market Research Report: Information by Conjunctivitis Type (Bacterial, Allergic, Viral and Chemical), Drug Class (Antibiotics, Mast Cell Stabilizers, Steroids and others), Route of Administration (Topical, Oral, Intra-Vitreal and others), End Users (Hospitals and Clinics and Specialty Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/1873-HCR | February, 2021 | Region : Global

Conjunctivitis Drugs Market Scenario


Conjunctivitis Drugs Market is expected to register 3.1% CAGR during the forecast period of 2019 to 2025 and will be valued at USD 1.18 Billion in 2025.


Conjunctivitis is commonly known as “pink eye” is an inflammation or swelling of the conjunctiva.


The prevalence of conjunctivitis or pink eye is increasing globally, fueling market growth. Conjunctivitis drugs are used for the treatment of conjunctivitis.  There are various types of conjunctivitis including bacterial, allergic, viral, and chemical. Conjunctivitis affects millions of people and imposes economic and social burdens. In the US, it is estimated that acute conjunctivitis affects about 6 million people annually. The major factors influencing the growth of the market include increasing prevalence of conjunctivitis. Bacterial conjunctivitis is the second most common cause and is responsible for the majority 50–75% of the cases in children. It is found that primary care physicians are the first point of treatment for most of the conjunctivitis patients rather than eye care professionals. About 1% of the visits for primary care offices in the US are associated with conjunctivitis. Moreover, a rise in hygiene and awareness, growing expenditure on health, greater exposure to allergens and infective agents, and the contagious nature of the disease are expected to drive the growth of the market.


Furthermore, factors such as appropriate diagnosis for viral conjunctivitis and limited awareness regarding advanced technologies are hampering the growth of the global market.


Segmentation


The Conjunctivitis Drugs Market is segmented based on conjunctivitis type, drug class, route of administration, end users, and region.


The conjunctivitis drugs market, by conjunctivitis type, is segmented into bacterial, allergic, viral, and chemical. The bacterial segment is further classified into hyperacute bacterial conjunctivitis, acute bacterial conjunctivitis, and chronic bacterial conjunctivitis. The allergic segment is further classified into atopic keratoconjunctivitis, simple allergic conjunctivitis, seasonal conjunctivitis, vernal conjunctivitis, and giant papillary conjunctivitis.


Viral conjunctivitis was the largest segment of the market, as viruses cause up to 80% of all cases of acute conjunctivitis. Viral conjunctivitis is more prevalent in summer and is the most common cause of infectious conjunctivitis across the globe. Furthermore, bacterial conjunctivitis expected to be the fastest-growing segment, as about 1.8% to 5.6% of all acute conjunctivitis is caused by chlamydia. Allergic conjunctivitis affects about 40 percent of the population, but only a small number of individuals pursue medical care.


Chemical conjunctivitis accounted for the least conjunctivitis drugs market share. Chemical conjunctivitis represents between 11.5–22.1% of ocular trauma. 


Based on drug class, the conjunctivitis drugs market is segmented into antibiotics, mast cell stabilizers, steroids, and others


Based on the administration, the conjunctivitis drugs market is segmented into topical, oral, intra-vitreal, and others. The topical antibiotics segment accounted for the major market share as these products are most effective in reducing the period of conjunctivitis.


Based on end user, the conjunctivitis drugs market is segmented into hospitals and clinics and specialty centers.


In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The conjunctivitis drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European conjunctivitis drug market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The conjunctivitis drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The conjunctivitis drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key Players


Some of the key players operating in the conjunctivitis drugs global market are Akorn Pharmaceuticals (US), Alcon/ Novartis AG (Switzerland), Allergan Plc (Ireland), Bausch & Lomb (US), Actavis Plc (US), Pfizer Inc (US), Merck & Co. Inc. (US), Lupin Limited (India), and Valeant Pharmaceuticals (Canada).


Regional Market Summary


Global Conjunctivitis Drugs Market Share (%), by Region, 2018  Conjunctivitis Drugs Market


Sources: MRFR Analysis


The Americas dominated the global conjunctivitis drugs market owing to the increasing awareness among the people, the presence of major manufacturers, the growing adoption of online purchasing medicine increasing prevalence of conjunctivitis and others. According to a study it was found that about 3 million cases conjunctivitis occurs in the US annually.


In 2018, Europe was the second-largest regional market. However, Asia-Pacific is expected to grow with the fastest growth rate throughout the forecast period due to the increasing investments by market players in the region. On the other hand, the Middle East & Africa holds the least share in the global conjunctivitis drugs market due to the low economic development, especially in Africa.


Global Conjunctivitis Drugs Market, by Conjunctivitis Type



  • Bacterial

    • Hyperacute Bacterial Conjunctivitis

    • Acute Bacterial Conjunctivitis

    • Chronic Bacterial Conjunctivitis



  • Allergic

    • Atopic Keratoconjunctivitis

    • Simple Allergic Conjunctivitis

    • Seasonal Conjunctivitis

    • Vernal Conjunctivitis

    • Giant Papillary Conjunctivitis



  • Viral

  • Chemical


Global Conjunctivitis Drugs Market, by Drug Class



  • Antibiotics

  • Mast Cell Stabilizers

  • Steroids

  • Others


Global Conjunctivitis Drugs Market, by Route of Administration



  • Topical

  • Oral

  • Intra-Vitreal

  • Others


Global Conjunctivitis Drugs Market, by End Users



  • Hospitals and Clinics

  • Specialty Centers

  • Others


Global Conjunctivitis Drugs Market, by Region



  • Americas

    • North America

    • US

    • Canada





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Pharmaceutical companies

  • Government research institutes

  • Academic institutes and universities

  • Venture capitalists

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.2.1 R&D and Designing

5.2.2 Manufacturing

5.2.3 Distribution & Sales

5.2.4 Post-Sales Review

Chapter 6. Global Conjunctivitis Drugs Market, by Conjunctivitis Type

6.1 Overview

6.2 Bacterial

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.1 Hyperacute Bacterial Conjunctivitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Acute Bacterial Conjunctivitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3 Chronic Bacterial Conjunctivitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Allergic

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.1 Atopic Keratoconjunctivitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.2 Simple Allergic Conjunctivitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.3 Seasonal Conjunctivitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.4 Vernal Conjunctivitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.5 Giant Papillary Conjunctivitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Viral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Chemical

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Conjunctivitis Drugs Market, by Drug Class

7.1 Overview

7.2 Antibiotics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Mast Cell Stabilizers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Steroids

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Conjunctivitis Drugs Market, by Route of Administration

8.1 Overview

8.2 Topical

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Oral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Intra-Vitreal

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Conjunctivitis Drugs Market, by End User

9.1 Overview

9.2 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3 Specialty Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 10. Global Conjunctivitis Drugs Market, by Region

10.1 Overview

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Overview

11.2 Competitive Analysis

Chapter 12. Company Profile

12.1 Akorn Pharmaceuticals.

12.1.1 Company Overview

12.1.2 Products/Services Offered

12.1.3 Financial Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.1.6 Key Strategies

12.2 Alcon/ Novartis AG.

12.2.1 Company Overview

12.2.2 Products/Services Offered

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.2.6 Key Strategies

12.3 Allergan Plc.

12.3.1 Company Overview

12.3.2 Products/Services Offered

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.3.6 Key Strategies

12.4 Bausch & Lomb.

12.4.1 Company Overview

12.4.2 Products/Services Offered

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.4.6 Key Strategies

12.5 Actavis Plc.

12.5.1 Company Overview

12.5.2 Products/Services Offered

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.5.6 Key Strategies

12.6 Pfizer Inc

12.6.1 Company Overview

12.6.2 Products/Services Offered

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.6.6 Key Strategies

12.7 Merck & Co. Inc.

12.7.1 Overview

12.7.2 Products/Services Offered

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.7.6 Key Strategies

12.8 Lupin Limited

12.8.1 Overview

12.8.2 Products/Services Offered

12.8.3 Financial Overview

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.8.6 Key Strategies

12.9 Valeant Pharmaceuticals.

12.9.1 Overview

12.9.2 Products/Services Offered

12.9.3 Financial Overview

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.9.6 Key Strategies

12.10 Others.

Chapter 13 Appendix

13.1 References

13.2 Related Reports


LIST OF TABLES

Table 1 Global Conjunctivitis Drugs Market Synopsis, 2020-2027

Table 2 Global Conjunctivitis Drugs Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 4 Global Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 5 Global Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 6 Global Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 7 Global Conjunctivitis Drugs Market, by Region, 2020-2027 (USD Million)

Table 8 Americas: Conjunctivitis Drugs Market, by Region, 2020 and 2025

Table 9 Americas: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 10 Americas: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 11 Americas: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 12 Americas Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 13 North America: Conjunctivitis Drugs Market, by Country, 2020-2027 (USD Million)

Table 14 North America: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 15 North America: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 16 North America: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 17 North Americas Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 18 US: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 19 US: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 20 US: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 21 US: Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 22 Canada: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 23 Canada: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 24 Canada: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 25 Canada: Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 26 Latin America: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 27 Latin America: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 28 Latin America: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 29 Latin America: Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 30 Europe: Conjunctivitis Drugs Market, by Region, 2020-2027 (USD Million)

Table 31 Europe: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 32 Europe: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 33 Europe: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 34 Europe: Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 35 Western Europe: Conjunctivitis Drugs Market, by Country, 2020-2027 (USD Million)

Table 36 Western Europe: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 37 Western Europe: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 38 Western Europe: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 39 Western Europe: Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 40 Eastern Europe: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 41 Eastern Europe: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 42 Eastern Europe: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 43 Eastern Europe: Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 44 Asia-Pacific: Conjunctivitis Drugs Market, by Country, 2020-2027 (USD Million)

Table 45 Asia-Pacific: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 46 Asia-Pacific: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 47 Asia-Pacific: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 48 Asia-Pacific: Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)

Table 49 Middle East & Africa: Conjunctivitis Drugs Market, by Region, 2020-2027 (USD Million)

Table 50 Middle East & Africa: Conjunctivitis Drugs Market, by Conjunctivitis Type, 2020-2027 (USD Million)

Table 51 Middle East & Africa: Conjunctivitis Drugs Market, by Drug Class, 2020-2027 (USD Million)

Table 52 Middle East & Africa: Conjunctivitis Drugs Market, by Route of Administration, 2020-2027 (USD Million)

Table 53 Middle East & Africa: Conjunctivitis Drugs Market, by End User, 2020-2027 (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure of the Global Conjunctivitis Drugs Market

Figure 3 Market Dynamics of the Global Conjunctivitis Drugs Market

Figure 4 Global Conjunctivitis Drugs Market Share, by Conjunctivitis Type, 2020 (%)

Figure 5 Global Conjunctivitis Drugs Market Share, by Conjunctivitis Type, 2020 (USD Million)

Figure 6 Global Conjunctivitis Drugs Market Share, by Drug Class, 2020 (%)

Figure 7 Global Conjunctivitis Drugs Market Share, by Drug Class, 2020 (USD Million)

Figure 8 Global Conjunctivitis Drugs Market Share, by Route of Administration, 2020 (%)

Figure 9 Global Conjunctivitis Drugs Market Share, by Route of Administration, 2020 (USD Million)

Figure 10 Global Conjunctivitis Drugs Market Share, by End User, 2020 (%)

Figure 11 Global Conjunctivitis Drugs Market Share, by End User, 2020 (USD Million)

Figure 12 Global Conjunctivitis Drugs Market Share, by Region, 2020 (%)

Figure 13 Americas: Conjunctivitis Drugs Market Share, by Region, 2020 (%)

Figure 14 North America: Conjunctivitis Drugs Market Share, by Country, 2020 (%)

Figure 15 Europe: Conjunctivitis Drugs Market Share, by Region, 2020 (%)

Figure 17 Asia-Pacific: Conjunctivitis Drugs Market Share, by Country, 2020 (%)

Figure 19 Middle East & Africa: Conjunctivitis Drugs Market Share, by Region, 2020 (%)

Figure 21 Global Conjunctivitis Drugs Market: Company Share Analysis, 2020 (%)

Figure 23 Akorn Pharmaceuticals.: Key Financials

Figure 25 Akorn Pharmaceuticals.: Segmental Revenue

Figure 27 Akorn Pharmaceuticals.: Regional Revenue

Figure 29 Alcon/ Novartis AG

Figure 31 Allergan Plc

Figure 33 Bausch & Lomb

Figure 35 Actavis Plc.

Figure 37 Pfizer Inc.

Figure 39 Merck & Co. Inc.

Figure 41 Lupin Limited.

Figure 43 Valeant Pharmaceuticals

Conjunctivitis Drugs Market